By Fineline Cube 
China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer of induced pluripotent stem cells (iPSC) therapies, reportedly raised close to RMB 100 million (USD 13.8 million) in a Pre-Series A financing round. Investors included Canton Venture Capital, Wanlian Tianze Capital, JIN CAPITAL, and existing shareholders. The proceeds will be used to advance the IND filing and IIT real-world study for IDA-001, an iPSC therapy for Parkinson’s disease.
Company Overview
Founded in 2019, Regenverse Therapeutics is focused on developing iPSC-derived universal off-the-shelf cell therapies for the treatment of tumors and nervous system diseases. The company boasts advanced technologies in iPSC reprogramming and cell banking, immune cell and neural cell differentiation, and gene modification to construct engineered iPS cell lines.
Pipeline Development
Regenverse Therapeutics is also developing iNK001, an iPSC-derived natural killer cell therapy, and a program targeting Huntington’s disease. The funding will support the advancement of these innovative therapies, positioning the company at the forefront of iPSC-based treatments.-Fineline Info & Tech